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Purpose: To assess the performance of multiparametric magnetic resonance imaging (mp-MRI) in patients with previous negative
transrectal ultrasound (TRUS) guided prostate biopsy.
Materials and methods: Fifty-four patients with at least 1 previous negative TRUS prostate biopsy underwent mp-MRI in the form of
T2-weighted, diffusion-weighted, and dynamic contrast-enhanced imaging. This was followed by transperineal template systematic prostate
biopsies. Analysis was done based on 2 sectors per prostate, right and left (108 sectors out of 54 prostates). mp-MRI was scored using an
ordinal scale 1 to 5 based on the suspicion of the presence of clinically signiﬁcant disease. We used 6 different deﬁnitions for clinically
signiﬁcant disease and tested the performance of mp-MRI at each single deﬁnition.
Results: Median age was 64 (range, 39–75), median PSA level was 10 (range, 2–23), and median number of biopsies was 45 (range,
21–137). Cancer of any volume and any grade was detected in 34 of 54 (63%) patients. mp-MRI accuracy at detection of clinically
signiﬁcant cancer using University College London (UCL) deﬁnition 2 (any Gleason score of 4 or maximum cancer core length of ≥4 mm or
both) showed sensitivity of 76%, speciﬁcity of 42%, positive predictive value of 38%, and negative predictive value of 79%. For a different
deﬁnition of signiﬁcant tumor (UCL deﬁnition 1; dominant Gleason score 4 or maximum cancer core length ≥6 mm or both), the sensitivity
was 90%, speciﬁcity 42%, positive predictive value 26%, and negative predictive value 95%.
Conclusions: mp-MRI showed good performance at both detection and ruling out clinically signiﬁcant disease, according to the
deﬁnition used. mp-MRI can then be used as a triage test in the population with persistently elevated or rising PSA levels to select patients
that can avoid unnecessary prostate biopsy. r 2014 Elsevier Inc. All rights reserved.
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We know that transrectal biopsy misses signiﬁcant prostate
cancers, because of both a random sampling error (repeat
biopsies using the same technique will detect tumor in aroundmatter r 2014 Elsevier Inc. All rights reserved.
.urolonc.2013.06.007
94; fax: þ44-20-3447-9303.
ed.azeez.10@ucl.ac.uk (M. Abd-Alazeez).a quarter [1]), and because between a quarter and a third of
signiﬁcant tumors lie in the anterior part of the gland, based
on studies of radical prostatectomy specimens [2].
Several studies have recently documented an incidence
of tumors in men with a negative biopsy but persistently
elevated PSA level. A study using systematic transperineal
mapping biopsy showed tumor in 57%, with the majority of
positive cores lying anteriorly [3]. Others have found tumor
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imaging (MRI) ﬁndings are used to target biopsy.
Recent data have suggested that most signiﬁcant (deﬁned
as40.5 mL) tumors are detected on MRI, including those
in the anterior part of the gland [6,7], with diffusion
especially effective in the latter [4]. Our aim was to assess
the performance of multiparametric MRI (mp-MRI) in men
with a continuing suspicion of tumor but negative TRUS
biopsy, by prospective comparison of MRI ﬁndings with
systematic transperineal mapping biopsies. Such mapping
biopsies have a high sensitivity for signiﬁcant disease and
are the best method we have for conﬁrming absence of
disease within the prostate: men without tumor would rarely
be subjected to prostatectomy [8].2. Material and methods
Research ethics committee exemption was granted for
this single institution study. A total of 58 men with at least 1
negative TRUS-guided prostate biopsy underwent mp-MRI
(index test) followed by template prostate mapping biopsy
(reference standard). Four men were excluded from the
study as they received limited template biopsy (less than 20
cores were taken). This gives a total number of 54 patients
included in the study. Patients had between 1 and 3 prior
negative biopsies (33 had previous 1 negative set of bio-
psies, 16 had previous 2 negative sets of biopsies, and 5 had
previous 3 negative sets of biopsies). Most of the patients
included in the study were referred from other health care
centers to our tertiary referral hospital. Although we do not
have a complete record of the number of cores taken during
each biopsy at the peripheral centers, it is considered stan-
dard practice at the referring units to take at least 10 to 12
core biopsies.
All patients included in the study had either increasing or
persistently high PSA level.
2.1. MRI (index test)
MRI comprised T2-weighted (T2W), diffusion-weighted
(DW), and dynamic contrast-enhanced (DCE) imaging with
either 1.5 T (Siemens Avanto, n ¼ 49) or 3 T (Philips
Achieva, n ¼ 5) machines. In each case, a multichannel
pelvic-phased array coil was used. Contrast was gadoterate
meglumine (dotarem, Guerbet, France) at a dose of at leastTable 1
Detailed MRI scan parameters
TR TE
Flip
angle, deg
Plane
1. T2 TSE 5,170 92 180 Axial and coronal
2. VIBE fat saturation 5.61 2.52 15 Axial
3. Diffusion (b values:
0, 150, 500, and 1,000)
2,200 Min (o98) Axial
4. Diffusion (b ¼ 1,400) 2,200 Min (o98) Axial0.1 mmol/kg, administered at 3 mL/s. The sequence param-
eters for the 1.5-T scans are shown in Table 1; each spe-
ciﬁcation was exceeded at 3 T, and in each case the scans
conformed to the recommended parameters of the recent
European Society of Urogenital Radiology guidelines on
mp-MRI [9].
Eight radiologists, of 3 to 8 years of experience, reported
all the mp-MR images using a score from 1 to 5 as in the
recent European Guidelines [9]. In 5 cases, the initial report
did not contain a numerical score, and 1 was generated by one
radiologist (A.K.) based on the report text only. mp-MRI was
performed in a blinded manner to the template biopsy as all
imaging reports were committed to the electronic medical
record before the biopsy result became available.2.2. Template biopsy (reference standard)
All patients underwent systematic template prostate
mapping biopsy using a brachytherapy grid under general
anesthesia in the method previously described by Barzell
and Melamed [10]. Basal and apical cores were obtained
routinely, and the minimum number of samples was 20.
For assessment of the performance of MRI, we analyzed
the prostate in halves (right and left), so that there were 108
sectors (54 patients). To determine the proportion of tumors
lying anteriorly on histology, we considered anterior cores
to lie in front of an imaginary transverse line drawn through
the urethra at midgland level. Biopsy cores taken from the
lateral part of the prostate (according to Barzell's deﬁni-
tions) were considered posterior. Whenever a suspected
lesion crossed the midline on MRI, both prostate halves
were attributed the same scoring for that lesion.
Fifteen patients had additional targeted biopsies besides
the systematic template prostate biopsies. This was done
based on cognitive registration. In other words, the operator
took biopsies from the 20 Barzell zones then took additional
biopsies from an area of the prostate deemed to be suspi-
cious or harbor cancer on MRI (score ≥ 3).2.3. Target conditions (Table 2)
The pathological outputs from the reference test were
grouped into a number of deﬁnitions of clinical signiﬁcance,
or target conditions [11,12] to reﬂect the fact that no uni-
versally accepted deﬁnition currently exists. The histologicalSlice
thickness, mm
Matrix size
Field of
view, mm
Time for scan
3 (10% gap) 256  256 180  180 3 min 54 s (ax), 4 min 18 s (cor)
3 (20% gap) 192  192 260  260 7 min (17 s per acquisition)
5 172  172 260  260 5 min 44 s (16 averages)
5 172  172 320  320 3 min 39 s (32 averages)
Table 2
Deﬁnitions of clinical signiﬁcance used as target conditions in the reference
test, template prostate mapping
Deﬁnition of clinically
signiﬁcant prostate cancer
Maximum cancer core
length (CCLmax)
Gleason
score
UCL deﬁnition 1 ≥6 mm or ≥4 þ 3, or both
UCL deﬁnition 2 ≥4 mm or ≥3 þ 4, or both
Gleason score ≥4 þ 3 Any ≥4 þ 3
Gleason score ≥3 þ 4 Any ≥3 þ 4
CCLmax ≥6 mm ≥6 mm Any
CCLmax ≥4 mm ≥4 mm Any
Table 3
Baseline demographics of 54 men, with prior negative TRUS biopsy,
undergoing mp-MRI followed by template prostate mapping
Age, y (median, range) 64 (39–75)
PSA (median, range) 10 (2–23)
Prostate volume (median, range) 53 (19–136)
Number with no cancer on TPM, n (%) 20/54 (37%)
Number with cancer on TPM, n (%) 34/54 (63%)
Number of biopsies at TPM (median, range) 45 (21–137)
Gleason score on TPM, n (%)
6 16/34 (47%)
7 (3 þ 4) 13/34 (38%)
7 (4 þ 3) 5/34 (15%)
≥8 0/34 (0%)
Table 4
Correlation between different MRI scores and systematic template mapping
biopsy ﬁndings based on Gleason grade
No
cancer
Gleason
3 þ 3
Gleason
3 þ 4
Gleason
4 þ 3
Total
MRI score 1 0 0 0 0 0
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interpreting the Gleason grading, the one used before the
International Society of Urological Pathology 2005 guidelines
[13]. In other words, Gleason scoring was based on the most
frequent pattern and not the highest grade detected on
histological analysis. Further, the cancer core length was
reported as the actual amount of cancer seen in each core
without counting the intervening areas of benign glands [14].
2.4. Statistical analysis
An mp-MRI score of ≥3 was used to designate a positive
index test for the purpose of ruling out clinically signiﬁcant
disease. The effect of varying this threshold to ≥4 was also
evaluated for predicting clinically signiﬁcant disease. If the
mp-MRI was positive in a sector proven to harbor clinically
insigniﬁcant disease, according to the deﬁnition used, this
area was deemed as a false positive. Accuracy ﬁgures
(sensitivity, speciﬁcity, and positive and negative predictive
values), together with 95% conﬁdence intervals (95% CIs),
were calculated for the performance of mp-MRI at each
deﬁnition of signiﬁcant disease.
2.5. Primary objective
To assess the ability of mp-MRI (with a score of ≥3/5
considered positive) to detect UCL deﬁnition 2 of clinically
signiﬁcant disease, deﬁned as any cancer with Gleason
pattern 4 or greater (≥3 þ 4) or maximum cancer core
length ≥4 mm or both.
2.6. Secondary objectives
First, to examine the performance of the test when: (1)
varying the histological deﬁnition of clinically signiﬁcant
disease and (2) varying the MRI threshold of positivity from
3/5 to 4/5. Second, we aimed to determine the distribution
of tumors found at template biopsy—in particular, the
proportion that lay anterior to the urethra.MRI score 2 26 10 3 0 39
MRI score 3 23 9 2 1 35
MRI score 4 7 7 5 4 23
MRI score 5 1 2 8 0 11
Total 57 28 18 5 1083. Results
Baseline demographic data are shown in Table 3.Cancer of any grade or burden was identiﬁed in 34 of 54
(63%) patients.
mp-MRI was ≥3 in 45 patients. Targeted biopsies (range
2–9) were taken in 15 patients and showed cancer in 8 of 16
(53%) patients. None of those patients had cancer only on
the targeted area.
Of 34 patients with a positive biopsy, 16 patients (47%) had
an anterior tumor only, 3 (9%) had a posterior tumor only, and
15 (44%) had a tumor in both anterior and posterior cores.
Table 4 illustrates the correlation between different MRI
scores and systematic template mapping biopsy ﬁndings
based on Gleason grade.3.1. Primary outcome
In ruling out the presence of any Gleason score ≥4 or maxi-
mum cancer core length ≥4 mm (UCL deﬁnition 2) or both,
mp-MRI had a sensitivity and negative predictive value (NPV)
of 76% (95% CI, 59%–91%) and 79% (95% CI, 66%–92%),
respectively (Table 5).3.2. Secondary outcomes
The performance of the test for different levels of clinical
signiﬁcance and at different MRI thresholds is shown in
Tables 6 and 7. At mp-MRI threshold of ≥3, both
sensitivity and NPV for detection of cancers of Gleason
score ≥4 þ 3 were 100% (95% CI, 100%–100%), whereas
Table 5
The performance characteristics of mp-MRI with a radiological score of ≥3 to detect and rule out clinically signiﬁcant cancer on TPM at multiple levels of
signiﬁcance (95% conﬁdence intervals in parentheses)
Classiﬁcation ROI TP FN TN FP SENS SPEC PPV NPV
UCL2 108 26 8 31 43 76 42 38 79
(5991) (3052) (2549) (6692)
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100%) and 92% (95% CI, 82%–100%), respectively.4. Discussion
The use of systematic transperineal biopsy for veriﬁca-
tion enabled us to estimate the sensitivity and negative
predictive value of mp-MRI in a group of men with
previous negative biopsy—something that has been difﬁcult
in most previous studies that have used targeted biopsy. Our
main ﬁnding was of a sensitivity of 76% for clinically
signiﬁcant disease (UCL Def 2), based on an analysis at
half-gland level, with sensitivity of 87% for any Gleason 4
element and 100% for tumors with dominant Gleason 4.
Speciﬁcity was fairly low (38%–46%), though improved if
a threshold of 4/5 was used to deﬁne positive disease (71%–
86%). However, using a score of 4/5 (“likely” rather than
“equivocal”) as the deﬁnition for signiﬁcant disease means
that even some tumors with dominant Gleason 4 elements
would be missed.
It is becoming clear that small amounts of low-grade
tumor are both unlikely to harm the patient [12] and
unlikely to be detected on MRI [7]. Because the deﬁnitions
of clinically signiﬁcant disease vary so much, we analyzed
the performance of MRI at a number of levels. The
appropriate deﬁnition of course varies with the patient: in
a relatively old man with comorbidities, exclusion of
dominant Gleason 4 disease may be all that is necessary,
whereas in a younger man, the exclusion of UCL deﬁnition
2 (o4 mm and no Gleason 4) may be more appropriate.Table 6
The performance characteristics of mp-MRI with a radiological score of ≥3 to de
signiﬁcance (95% conﬁdence intervals in parentheses)
Classiﬁcation ROI TP FN TN FP
UCL1 108 18 2 37 51
Gleason 4 þ 3 108 5 0 39 64
Gleason 3 þ 4 108 20 3 36 49
CCLmax ≥6 108 16 2 37 53
CCLmax ≥4 108 20 7 32 49
Any cancer 108 38 13 26 31We used the half gland for analysis because of a
compromise. Overall, in a study with a large number of
patients, the most clinically relevant level of analysis is the
whole gland: equivalent to the question “have we missed a
signiﬁcant tumor in this patient.” However, we had a
smaller number of patients scored negative on MRI (n ¼
9/54, 17%) than one would expect in the group of patients
with persistently elevated PSA level and a previous
negative biopsy. The number of halves that scored negative
was much higher—39 of 108 (36%) (apparent disease on
MRI is often unilateral).
It would have been possible to analyze the prostate at the
level of a number of smaller quadrants, but this has a
number of drawbacks. Firstly, boundary effects increase, so
that complicated rules must be devised to account for
imperfect registration of MRI and biopsy or prostatectomy
specimens. Secondly, the clinical question is usually
at the level of the prostate, or half gland—“does this patient
have disease?” or “do I only need to treat half the
gland?” Quadrant analysis results in a spurious apparent
increase in speciﬁcity [15] and is difﬁcult to interpret
clinically.
4.1. Previous studies
Two important parameters have been measured in
previous studies: the overall detection rate of cancer in
men with a previous negative biopsy, and the proportion of
tumors lying anteriorly. A targeted biopsy technique, as
used in almost all previous papers, precludes the estimation
of sensitivity and speciﬁcity.tect and rule out clinically signiﬁcant cancer on TPM at multiple levels of
SEN SPEC PPV NPV
90 42 26 95
(74100) (3050) (1636) (86100)
100 38 7 100
(100100) (2847) (2–14) (100100)
87 42 29 92
(70100) (3152) (1940) (82100)
89 41 23 95
(71100) (3051) (1433) (86100)
74 39 29 82
(5490) (2849) (1939) (6993)
74 45 55 66
(6186) (3159) (4367) (5182)
Table 7
The performance characteristics of mp-MRI with a radiological score of ≥4 to detect and rule out clinically signiﬁcant cancer on TPM at multiple levels of
signiﬁcance (95% conﬁdence intervals in parentheses)
Classiﬁcation ROI TP FN TN FP SENS SPEC PPV NPV
UCL2 108 23 11 63 11 67 85 67 85
(5083) (7693) (4884) (7793)
UCL1 108 16 4 70 18 80 80 47 94
(6091) (7188) (3164) (8999)
Gleason 4 þ 3 108 4 1 73 30 79 71 12 99
(29100) (6279) (223) (95100)
Gleason 3 þ 4 108 17 6 68 17 74 80 50 92
(5590) (7189) (3269) (8597)
CCLmax ≥6 108 14 4 70 20 77 78 41 94
(5795) (6986) (2659) (8999)
CCLmax ≥4 108 17 10 64 17 62 79 49 86
(4180) (7088) (3268) (7893)
Any cancer 108 26 25 49 8 51 86 76 66
(3865) (7695) (6191) (5577)
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our ﬁnding of any cancer in 63% and signiﬁcant in 43% is
similar to several previous studies: 40% for any tumor in 1
group of 43 patients [4], 42% for any tumor in men
undergoing template biopsy without MRI (n ¼ 102) [16],
48% in a recently published study [17], and 59% for
signiﬁcant tumor in another group of patients with suspi-
cious foci on MRI [4,5].
Several groups have provided estimates of the proportion
of tumors lying anteriorly: one group using targeted biopsies
found that missed tumors were in the “most ventral part of the
transition zone” or anterior horns in a total of 68% of patients
[5], and another group found (again using targeted cores) that
76% of missed tumors lay in the transition zone [4]. Finally, a
group using template biopsies but not MRI found that 59% of
tumors lay in the transition zone or anterior parts of the
peripheral zone [16]. Again, these results are in agreement
with those obtained using our systematic biopsy technique,
where the great majority of patients (92%) had some anterior
tumor, and 47% had only anterior tumor.
Our ﬁnding of a relatively low speciﬁcity of MRI if 3/5 is
considered positive is consistent with the study by Franiel et al.
[18]. Fifty-four patients with at least 1 prior negative prostate
biopsy underwent mp-MRI including spectroscopy. MRI-
guided biopsies were obtained and cancer was found in 21
of 54 (39%) patients. Out of 178 lesions detected on MRI, 53
were positive on biopsy: a positive predictive value of 30%.
Arumainayagam et al. [19] recently evaluated the
performance of mp-MRI in the detection of clinically
signiﬁcant prostate cancer. Their cohort comprised 3 differ-
ent patient categories; those with known low-risk or low-
intermediate-risk prostate cancer (n ¼ 51), those with
previous negative biopsies (n ¼ 10), and those with no
prior prostate biopsy (n ¼ 3). Two thresholds, deﬁnitions 1
and 2, were used to describe clinically signiﬁcant disease.
These are comparable to our UCL deﬁnitions 1 and 2,
respectively. In ruling out prostate cancer, they had a
similar negative predictive value that reached up to 95%.Perhaps the largest limitation of this study is that the
decision to proceed to biopsy was based partly on the MRI
ﬁndings. This means our estimates of disease prevalence are
likely overestimates. However, to some extent this is miti-
gated by the half-gland analysis and the use of systematic
biopsies. At the same time, one would expect to ﬁnd a low
NPV of MRI in a population with a high disease prevalence.
However, our NPV was quite high; 79% to 100% for various
deﬁnitions of clinically signiﬁcant disease.
Second, although template biopsies perform well for the
detection of signiﬁcant disease (both in theoretical studies
and in practice [20], with ﬁgures of up to 87% for the
detection of signiﬁcant tumor), they are arguably less
accurate than radical prostatectomy, and we are ultimately
using a core biopsy technique to estimate tumor signiﬁ-
cance. Although the technique for doing so has been
validated [21], it introduces another source of error.
Third, the scans were interpreted by many different
radiologists, and a small minority were performed on a
3 T machine (n ¼ 5). This introduces variability in the
performance of the diagnostic test, but it does represent
real-world experience, and each radiologist was a subspe-
cialist reporting at least 100 mp-MRIs per year.
4.2. Clinical implications
Although previous studies have shown that mp-MRI can
be used to detect prostate cancer in many men with
previously negative biopsies, they have been less effective
at answering the question “how reliable is a negative MRI?”
because of the targeted biopsy technique that is generally
employed. Our estimates of sensitivity suggest that MRI can
be very useful for excluding tumor in this group, and
preventing the need for rebiopsy. This is especially true
when the deﬁnition of signiﬁcant disease does not include
small tumors or those with a small Gleason 4 component.
The low positive predictive value of the test in our study
(and in others) implies that MRI cannot be used to reliably
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drawback if a positive MRI is seen as an indication to
biopsy—and though not the subject of this paper, as a map
for biopsy as well. It is then acting as a triage test: ruling out
disease in some, and triggering biopsy in others.5. Conclusions
Mp-MRI showed good performance at both detection
(sensitivity 76%–100%) and ruling out (NPV of 79%–
100%) clinically signiﬁcant disease, according to the
deﬁnition used. Therefore, we think that mp-MRI has the
potential to be used as a triage test in the population with
persistently elevated or rising PSA level to select patients
that can avoid unnecessary prostate biopsy.
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